nach oben

Journal of Neurology

Erschienen in:

26.05.2017 | Original Communication

Olfactory impairment in Parkinson’s disease is a consequence of central nervous system decline

verfasst von: Emilia Iannilli, Lars Stephan, Thomas Hummel, Heinz Reichmann, Antje Haehner

Erschienen in: Journal of Neurology | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Early diagnosis and timely treatment of Parkinson’s disease are essential factors to provide these patients with a longer period of a better quality of life. Olfactory loss is among the first non-motor symptoms of the disease; however, in light of the many causes of smell loss, it is a very unspecific biomarker and should only be used as part of a diagnostic test battery. In this study, we investigated the olfactory response in 71 subjects, consisting of Parkinson’s disease patients, hyposmic and anosmic patients of other causes, and normosmic individuals searching for sensitive, distinct biomarkers for which we used scalp event-related 64-channel electroencephalography and psychophysical tests. The analysis of the global field power indicated significant measurable differences between patients with Parkinson’s disease and otherwise olfactory dysfunctional and normosmic individuals. The localization of brain sources, in particular, provides evidence for differences in mainly late EEG-components suggesting a decline of central brain networks as a causal factor for olfactory loss in Parkinson’s disease. The findings indicate a different pattern of olfactory processing in patients with Parkinson’s disease compared to olfactory dysfunctions of other origin, which provide further insights into the mechanisms behind olfactory dysfunction in Parkinson’s.

Nur mit Berechtigung zugänglich

Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20(4):415–455CrossRefPubMed

Berg D, Postuma RB, Adler CH et al (2015) MDS research criteria for prodromal Parkinson’s disease. Mov Disord 30(12):1600–1611CrossRefPubMed

Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K (2004) Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res 318(1):121–134CrossRefPubMed

Del Tredici K, Rub U, De Vos RA, Bohl JR, Braak H (2002) Where does parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 61(5):413–426CrossRefPubMed

Haehner A, Boesveldt S, Berendse HW et al (2009) Prevalence of smell loss in Parkinson’s disease—a multicenter study. Parkinsonism Relat Disord 15(7):490–494CrossRefPubMed

Doty RL, Shaman P, Dann M (1984) Development of the University of Pennsylvania smell identification test: a standardized microencapsulated test of olfactory function. Physiol Behav 32(3):489–502CrossRefPubMed

Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G (1997) ‘Sniffin’ sticks’: olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. Chem Senses 22(1):39–52CrossRefPubMed

Mueller A, Reichman H, Livermore A, Hummel T (2002) Olfactory function in idiopathic Parkinson’s disease: results from cross-sectional studies in IPD patients and long-term follow-up of de-novo IPD patients. J Neural Transm 109:805–811CrossRef

Wenning GK, Shephard B, Hawkes C, Petruckevitch A, Lees A, Quinn N (1995) Olfactory function in atypical parkinsonian syndromes. Acta Neurol Scand 91(4):247–250CrossRefPubMed

10.

Whitcroft KL, Cuevas M, Haehner A, Hummel T (2017) Patterns of olfactory impairment reflect underlying disease etiology. Laryngoscope 127(2):291–295CrossRefPubMed

11.

Hummel T, Kobal G (2001) Olfactory event-related potentials. In: Simon SA, Nicolelis MAL (eds) Methods and frontiers in chemosensory research. CRC Press, Boca Raton, pp 129–164

12.

Harada H, Shiraishi K, Kato T (2003) Olfactory event-related potentials in normal subjects and patients with smell disorders. Clin Electroencephalogr 34(4):191–196CrossRefPubMed

13.

Picton TW, Lins OG, Scherg M (1994) Handbook of neurophysiology. Elsevier, Amsterdam

14.

Picton TW, Hillyard SA, Krausz HI, Galambos R (1974) Human auditory evoked potentials. I. Evaluation of components. Electroencephalogr Clin Neurophysiol 36(2):179–190CrossRefPubMed

15.

Kobal G, Plattig KH (1978) Objective olfactometry: methodological annotations for recording olfactory EEG-responses from the awake human. EEG EMG Z Elektroenzephalogr Elektromyogr Verwandte Geb 9(3):135–145PubMed

16.

Iannilli E, Beger M, Furer R, Hummel T (2015) A gustatory stimulator. J Neurosci Methods 255:12–16CrossRefPubMed

17.

Barz S, Hummel T, Pauli E, Majer M, Lang CJ, Kobal G (1997) Chemosensory event-related potentials in response to trigeminal and olfactory stimulation in idiopathic Parkinson’s disease. Neurology 49(5):1424–1431CrossRefPubMed

18.

Hawkes CH, Shephard BC, Daniel SE (1997) Olfactory dysfunction in Parkinson’s disease. J Neurol Neurosurg Psychiatry 62(5):436–446CrossRefPubMedPubMedCentral

19.

Bocquillon P, Bourriez JL, Palmero-Soler E, Defebvre L, Derambure P, Dujardin K (2015) Impaired early attentional processes in Parkinson’s disease: a high-resolution event-related potentials study. PLoS One 10(7):e0131654CrossRefPubMedPubMedCentral

20.

Solis-Vivanco R, Rodriguez-Violante M, Rodriguez-Agudelo Y, Schilmann A, Rodriguez-Ortiz U, Ricardo-Garcell J (2015) The P3a wave: a reliable neurophysiological measure of Parkinson’s disease duration and severity. Clin Neurophysiol 126(11):2142–2149CrossRefPubMed

21.

Martinez-Horta S, Riba J, de Bobadilla RF et al (2014) Apathy in Parkinson’s disease: neurophysiological evidence of impaired incentive processing. J Neurosci 34(17):5918–5926CrossRefPubMed

22.

Mensen A, Poryazova R, Schwartz S, Khatami R (2014) Humor as a reward mechanism: event-related potentials in the healthy and diseased brain. PLoS One 9(1):e85978CrossRefPubMedPubMedCentral

23.

Dietz J, Bradley MM, Jones J, Okun MS, Perlstein WM, Bowers D (2013) The late positive potential, emotion and apathy in Parkinson’s disease. Neuropsychologia 51(5):960–966CrossRefPubMedPubMedCentral

24.

Desmedt JE, Tomberg C, Noël P, Ozaki I (1990) Beware of the average reference in brain mapping. Electroencephalogr Clin Neurophysiol Suppl 41:22–27PubMed

25.

Lehmann D, Skrandies W (1980) Reference-free identification of components of checkerboard-evoked multichannel potential fields. Electroencephalogr Clin Neurophysiol 48(6):609–621CrossRefPubMed

26.

Pascual-Marqui RD, Lehmann D (1993) Comparison of topographic maps and the reference electrode: comments on two papers by Desmedt and collaborators. Electroencephalogr Clin Neurophysiol 88(530–531):534–536

27.

Litvan I, Bhatia KP, Burn DJ et al (2003) Movement Disorders Society Scientific Issues Committee report: SIC task force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 18(5):467–486CrossRefPubMed

28.

Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189–198CrossRefPubMed

29.

Kobal G, Klimek L, Wolfensberger M et al (2000) Multicenter investigation of 1,036 subjects using a standardized method for the assessment of olfactory function combining tests of odor identification, odor discrimination, and olfactory thresholds. Eur Arch Otorhinolaryngol 257(4):205–211CrossRefPubMed

30.

Peirce JW (2007) PsychoPy–psychophysics software in Python. J Neurosci Methods 162(1–2):8–13CrossRefPubMedPubMedCentral

31.

Halliday AM, Halliday E, Kriss A, McDonald WI, Mushin J (1976) The pattern-evoked potential in compression of the anterior visual pathways. Brain 99(2):357–374CrossRefPubMed

32.

Bodis-Wollner I, Yahr MD (1978) Measurements of visual evoked potentials in Parkinson’s disease. Brain 101(4):661–671CrossRefPubMed

33.

Bodis-Wollner I, Yahr MD, Mylin L, Thornton J (1982) Dopaminergic deficiency and delayed visual evoked potentials in humans. Ann Neurol 11(5):478–483CrossRefPubMed

34.

Peppe A, Stanzione P, Pierelli F, De Angelis D, Pierantozzi M, Bernardi G (1995) Visual alterations in de novo Parkinson’s disease: pattern electroretinogram latencies are more delayed and more reversible by levodopa than are visual evoked potentials. Neurology 45(6):1144–1148CrossRefPubMed

35.

Grave de Peralta Menendez R, Gonzalez Andino S, Lantz G, Michel CM, Landis T (2001) Noninvasive localization of electromagnetic epileptic activity. I. Method descriptions and simulations. Brain Topogr 14(2):131–137CrossRefPubMed

36.

Michel CM, Murray MM, Lantz G, Gonzalez S, Spinelli L, Grave de Peralta R (2004) EEG source imaging. Clin Neurophysiol 115(10):2195–2222CrossRefPubMed

37.

Pause BM, Sojka B, Krauel K, Ferstl R (1996) The nature of the late positive complex within the olfactory event-related potential (OERP). Psychophysiology 33(4):376–384CrossRefPubMed

38.

Allman JM, Hakeem A, Erwin JM, Nimchinsky E, Hof P (2001) The anterior cingulate cortex. The evolution of an interface between emotion and cognition. Ann N Y Acad Sci 935:107–117CrossRefPubMed

39.

Rosenberg-Katz K, Maidan I, Jacob Y, Giladi N, Mirelman A, Hausdorff JM (2016) Alterations in conflict monitoring are related to functional connectivity in Parkinson’s disease. Cortex 82:277–286CrossRefPubMed

40.

Gaspar P, Berger B, Febvret A, Vigny A, Henry JP (1989) Catecholamine innervation of the human cerebral cortex as revealed by comparative immunohistochemistry of tyrosine hydroxylase and dopamine-beta-hydroxylase. J Comp Neurol 279(2):249–271CrossRefPubMed

41.

Carter CS, Braver TS, Barch DM, Botvinick MM, Noll D, Cohen JD (1998) Anterior cingulate cortex, error detection, and the online monitoring of performance. Science 280(5364):747–749CrossRefPubMed

42.

Kuenig G, Leenders KL, Martin C, Magyar S, Schultz W (1999) Reward processing in Parkinsons disease A PET activation study. Neurology 52(2 suppl 2):A349

43.

Torack RM, Morris JC (1988) The association of ventral tegmental area histopathology with adult dementia. Arch Neurol 45(5):497–501CrossRefPubMed

44.

German DC, Manaye K, Smith WK, Woodward DJ, Saper CB (1989) Midbrain dopaminergic cell loss in Parkinson’s disease: computer visualization. Ann Neurol 26(4):507–514CrossRefPubMed

45.

Rinne JO, Rummukainen J, Paljarvi L, Rinne UK (1989) Dementia in Parkinson’s disease is related to neuronal loss in the medial substantia nigra. Ann Neurol 26(1):47–50CrossRefPubMed

46.

Grossman M, Crino P, Reivich M, Stern MB, Hurtig HI (1992) Attention and sentence processing deficits in Parkinson’s disease: the role of anterior cingulate cortex. Cereb Cortex 2(6):513–525CrossRefPubMed

47.

Witter MP, Groenewegen HJ, Lopes da Silva FH, Lohman AH (1989) Functional organization of the extrinsic and intrinsic circuitry of the parahippocampal region. Prog Neurobiol 33(3):161–253CrossRefPubMed

48.

Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL (1984) Alzheimer’s disease: cell-specific pathology isolates the hippocampal formation. Science 225(4667):1168–1170CrossRefPubMed

49.

Summerfield C, Junque C, Tolosa E et al (2005) Structural brain changes in Parkinson disease with dementia: a voxel-based morphometry study. Arch Neurol 62(2):281–285CrossRefPubMed

50.

Camicioli R, Moore MM, Kinney A, Corbridge E, Glassberg K, Kaye JA (2003) Parkinson’s disease is associated with hippocampal atrophy. Mov Disord 18(7):784–790CrossRefPubMed

51.

Xu Y, Yang J, Hu X, Shang H (2016) Voxel-based meta-analysis of gray matter volume reductions associated with cognitive impairment in Parkinson’s disease. J Neurol 263(6):1178–1187CrossRefPubMed

52.

Jahanshahi M, Jones CR, Zijlmans J et al (2010) Dopaminergic modulation of striato-frontal connectivity during motor timing in Parkinson’s disease. Brain 133(Pt 3):727–745CrossRefPubMed

53.

Farrer C, Frey SH, Van Horn JD et al (2008) The angular gyrus computes action awareness representations. Cereb Cortex 18(2):254–261CrossRefPubMed

54.

Seghier ML (2013) The angular gyrus: multiple functions and multiple subdivisions. Neuroscientist 19(1):43–61CrossRefPubMedPubMedCentral

55.

Seibyl JP, Marek KL, Quinlan D et al (1995) Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson’s disease. Ann Neurol 38(4):589–598CrossRefPubMed

56.

Gruzelier JH (1999) Functional neuropsychophysiological asymmetry in schizophrenia: a review and reorientation. Schizophr Bull 25(1):91–120CrossRefPubMed

57.

Innis RB, Seibyl JP, Scanley BE et al (1993) Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci USA 90(24):11965–11969CrossRefPubMedPubMedCentral

58.

Marek KL, Seibyl JP, Zoghbi SS et al (1996) [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson’s disease. Neurology 46(1):231–237CrossRefPubMed

Titel: Olfactory impairment in Parkinson’s disease is a consequence of central nervous system decline
verfasst von: Emilia Iannilli
Lars Stephan
Thomas Hummel
Heinz Reichmann
Antje Haehner
Publikationsdatum: 26.05.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Neurology / Ausgabe 6/2017
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-017-8521-0

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

22.04.2024 | DGIM 2024 | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Olfactory impairment in Parkinson’s disease is a consequence of central nervous system decline

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Checkpointhemmer auch bei MS sicher

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Neurologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2017

Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up study

Varicella zoster virus encephalitis in a patient with a solid carcinoma: a case report

Familial dysautonomia: a disease with hidden tears

High-intensity interval training in facioscapulohumeral muscular dystrophy type 1: a randomized clinical trial

Prevalence of Parkinson symptoms in patients with different peripheral vestibular disorders

Vaccines and multiple sclerosis: a systematic review

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Checkpointhemmer auch bei MS sicher

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Neurologie